Otros idiomas Pieris Pharmaceuticals, Inc.

Acciones

PIRS

US7207952026

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 29/04/2024			Varia. Cinco días.	Varia. 1 de enero.
11,71 ^USD	-0,09 %		+0,19 %	-19,57 %

29/03	Pieris Pharmaceuticals, Inc. informa de los resultados del ejercicio finalizado el 31 de diciembre de 2023	CI
05/01	Prime Medicine nombra nuevo director financiero a Foghorn Therapeutics	MT

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split	22/04
Pieris Pharmaceuticals Shares Fall After 1-for-80 Reverse Stock Split Announcement	19/04
Pieris Pharmaceuticals : Announces 1-for-80 Reverse Stock Split - Form 8-K	18/04
North American Morning Briefing : Powell Awaited -2-	03/04
Pieris Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03
Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential	28/03
Pieris Pharmaceuticals : Announces Strategy to Maximize Partnered Milestone and Royalty Potential - Form 8-K	27/03
North American Morning Briefing : Stocks Edge -2-	27/03
Prime Medicine Names Foghorn Therapeutics' CFO to be its New Finance Chief	05/01
North American Morning Briefing : Stocks Seen -2-	15/11
Pieris Pharmaceuticals: Q3 Earnings Snapshot	14/11
Pieris Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
North American Morning Briefing : Stock Futures -2-	08/11
Pieris Pharmaceuticals, Inc.(NasdaqCM:PIRS) dropped from S&P Global BMI Index	18/09/23
Vicore Pharma's New CEO to Formally Take Office	08/09/23
Dr. Hitto Kaufmann appointed Chief Scientific Officer of Hansa Biopharma	04/09/23
Sweden’s Hansa Biopharma Appoints New Chief Scientific Officer	01/09/23
Dr. Hitto Kaufmann appointed Chief Scientific Officer of Hansa Biopharma	01/09/23
Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific	18/08/23
Pieris Pharmaceuticals Says Patient Dosing in Cancer Drug Trial Triggers Milestone Payment From Boston Pharmaceuticals	17/08/23

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Pieris Pharmaceuticals, Inc.

Acciones

PIRS

US7207952026

Otros idiomas

Filtros